David Slade, MD
Ophthalmology · St George, UTNPI 1598918666
Payments from drug & device makers
What this record shows
This record is dominated by other: $5,447 of the $8,475 with a category attached, or 64.3%. Glaukos Corporation accounts for 64.8% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $5,612 and has fallen 96.5% since, to $197 in 2025.
Across 84 payments — averaging $100.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$5K
- Alcon$2K
- NEW World Medical,inc.$598
- AbbVie$275
- Aerie Pharmaceuticals, Inc.$95
- Sun Pharmaceutical Industries Inc.$44
- plus $179 from 8 others
Across 60 payments — averaging $2837.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$170K
What the payments were for
- Travel & lodging$6838%
- Food & beverage$2,28127%
- Gifts$641%
- Other$5,44764%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 3 | $5,496 |
| Alcon | 42 | $1,789 |
| NEW World Medical,inc. | 9 | $598 |
| AbbVie(2 entities) | 13 | $275 |
| Aerie Pharmaceuticals, Inc. | 5 | $95 |
| Sun Pharmaceutical Industries Inc. | 2 | $44 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $39 |
| Biotissue Holdings Inc. | 2 | $35 |
| Sight Sciences, Inc. | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Omeros Corporation | 1 | $18 |
| Bausch & Lomb Americas Inc. | 1 | $17 |
| Eyepoint US, Inc. | 1 | $16 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent Inject Trabecular Micro-Bypass System$5,447
- Clareon$1,012
- ARGOS$683
- Centurion$683
- AcrySof IQ PanOptix$129
How this compares
$8,475 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 697 | $28,085 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $12,006 |
| LumiganBimatoprost | 32 | $11,449 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $10,770 |
| MoxifloxacinMoxifloxacin Hcl | 519 | $10,517 |
| RestasisCyclosporine | 11 | $8,666 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $6,429 |
| Timolol Maleate | 406 | $3,877 |
| Ketorolac Tromethamine | 175 | $3,659 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 226 | $3,603 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $3,075 |
| Travoprost | 21 | $2,274 |
| Brimonidine Tartrate | 145 | $1,944 |
| Latanoprost | 262 | $1,806 |
| Dorzolamide Hcl | 49 | $930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis | $275 | $32,12167 claims |
| AlconSimbrinza | $1,789 | $10,77027 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $95 | $6,42918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in St George
- Sharon RichensSt George$26K
- Shawno MaySt George$4K
- William WagnerSt George$3K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.